← Leaderboards
Amrita Krishnan
University Of Southern California
$301,778
Attributed
$301,778
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $39K · FY2005–09$50K$37.5K$25K$12.5K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$301,778 · 13
By mechanism
M01$301,778 · 13
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Donald B Kohn$24,055,774
- John A Zaia$8,207,353
- Leslie Philip Weiner$6,552,756
- Smita Bhatia$27,398,641
- Thomas S Buchanan$21,929,119
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$80,540,126
- David T Scadden · Massachusetts General Hospital$40,987,034
- David A Williams · Indiana Univ-Purdue Univ At Indianapolis$36,503,708
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
Research focus
Hematopoietic Stem CellsClinical ResearchHuman Therapy EvaluationHuman SubjectRibozymesClinical TrialsHematopoietic Tissue TransplantationNeoplasm /Cancer ChemotherapyTissue /Cell CultureAids TherapyNonhodgkin'S LymphomaTransfection /Expression VectorColony Stimulating FactorHomologous TransplantationResearch PersonnelResourcesRetroviridaeGene TherapyEtoposideGrantNeoplasm /Cancer ImmunotherapyFundingCombination Cancer TherapyComputer Retrieval Of Information On Scientific Projects Database
Grant awards (18)
PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS$7,569
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$1,201
M01 · FY2008 · RR · contact PI
A PILOT STUDY OF SAFETY AND FEASIBILITY OF STEM CELL THERAPY FOR AIDS$1,106
M01 · FY2008 · RR · contact PI
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$3,875
M01 · FY2007 · RR · contact PI
PHASE I CLINICAL TRIAL OF 17-ALLYLAMINO-17-DEMETHOXY-GELDANAMYCIN (KOS-953)$968
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$33,748
M01 · FY2006 · RR · contact PI
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO$3,025
M01 · FY2006 · RR · contact PI
AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469$2,178
M01 · FY2006 · RR · contact PI
A PILOT STUDY OF YTTRIUM-90-LABELED ANTI-CD20 MONOCLONAL$24,791
M01 · FY2005 · RR
AN OPEN-LABEL STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF ORAL SCIO-469$6,198
M01 · FY2005 · RR
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO$4,305
M01 · FY2005 · RR
HIGH DOSE CHEMOTHERAPY AND COMBINATION ANTI-HIV THERAPY FOR HIV ASSOCIATED HO...$19,349
M01 · FY2004 · RR
RIBOZYMES IN PERIPHERAL BLOOD PROGENITOR CELLS$2,148
M01 · FY2004 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$0
M01 · FY2002 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$155,764
M01 · FY2001 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$0
M01 · FY2001 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$35,553
M01 · FY2000 · RR
HIGH DOSE CHEMO &STEM CELL TRANSPLANT IN HIV NON HODGKINS LYMPHOMA$0
M01 · FY2000 · RR